ORCHID PHARMA LIMITED
ORCHPHARMA · General/Diversified · NSE
₹567
Current Market Price
Fair Value (DCF)
₹404
Margin of Safety
-28.8%
Updated 7h ago
YieldIQ Score
54/100
Piotroski F-Score
4/9
Economic Moat
Moderate
Confidence
33%
ROE
—
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹2,875 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
7.9%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
15.0×
Leverage vs earnings
Interest Coverage
7.6×
EBIT covers interest
Current Ratio
2.83×
Short-term liquidity
Asset Turnover
0.54×
Revenue per ₹ of assets
Revenue CAGR (3Y)
17.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹566.8
Bear case
₹239.5
MoS -136.7%
Base case
₹403.74
MoS -40.4%
Bull case
₹509.35
MoS -11.3%
Ratio Trends
ORCHPHARMA · last 5 annual periods
ROE
7.9%
ROCE
10.0%
Operating Margin
—
Debt / Equity
0.14×
PE
—
EV / EBITDA
—
Historical Financials
ORCHPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹450 Cr | ₹560 Cr | ₹666 Cr | ₹819 Cr | ₹914 Cr | +19.4% |
| EBITDA | — | ₹62.1 Cr | ₹142 Cr | ₹142 Cr | ₹145 Cr | +23.5% |
| EBIT | ₹-43.9 Cr | ₹-28.4 Cr | ₹87.5 Cr | ₹108 Cr | — | — |
| PAT | ₹-117 Cr | ₹-2.0 Cr | ₹46.3 Cr | ₹94.7 Cr | ₹99.7 Cr | — |
| EPS (diluted) | ₹-28.55 | ₹-0.48 | ₹13.01 | ₹19.59 | — | — |
| CFO | ₹28.9 Cr | ₹89.0 Cr | ₹18.6 Cr | ₹131 Cr | ₹19.2 Cr | -9.7% |
| CapEx | — | — | — | — | ₹-150 Cr | — |
| FCF | — | — | — | — | ₹-131 Cr | — |
| Total Assets | — | ₹1111 Cr | ₹1225 Cr | ₹1552 Cr | ₹1688 Cr | +11.0% |
| Total Debt | — | — | ₹183 Cr | ₹14.0 Cr | ₹175 Cr | -1.1% |
| Shareholders' Equity | — | — | ₹689 Cr | ₹1218 Cr | ₹1267 Cr | +16.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ORCHPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| GUFICBIO GUFICBIO | — | — | Pending | 11.6% | — |
| BLISSGVS BLISSGVS | — | — | Pending | 7.7% | — |
| IOLCP IOLCP | — | — | Pending | 6.0% | — |
| RPGLIFE RPG LIFE SCIENCES LTD | -36.4% | 60 | Above Fair Value | 34.5% | — |
| UNICHEMLAB UNICHEMLAB | — | — | Pending | 5.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for ORCHPHARMA in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. ORCHID PHARMA LIMITED (ORCHPHARMA.NS) trades at 566.80 vs a model fair value of 403.74, a gap of -28.8%. Piotroski F-score: 4/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ORCHPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ORCHPHARMA →
Compare
Head-to-head with peers
Compare ORCHPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ORCHPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.